EnVVeno Medical to Present New VenoValve Efficacy Data at Charing Cross Symposium

enVVeno Medical Corporation (NASDAQ:NVNO) announced today that it will present updated efficacy data from its VenoValve U.S. pivotal trial at the 2024 Charing Cross International Symposium held from April 23-25 in London. The data comes from the Surgical Anti-reflux Venous Valve Endoprosthesis (SAVVE) trial and will be presented on April 24 by Dr. David Dexter. This long-term study assesses the use of bioprosthetic valves in patients with chronic deep venous reflux.

The presentation will focus on the updated Venous Clinical Severity Score (rVCSS), measuring improvements from the patient's baseline pre-implantation of the VenoValve. Data will cover 64 patient-years follow-up, highlighting the clinical advancements in treating severe Chronic Venous Insufficiency (CVI), which affects approximately 2.5 million new patients annually in the U.S. According to the company, the VenoValve has shown significant clinical improvement in patients who have previously not responded to conventional treatments.

This symposium, now in its 46th year, is a major event in the vascular community, attracting over 4,000 attendees annually. enVVeno Medical's presentation will likely be a significant point of interest given the novel approach of the VenoValve treatment and its potential implications for severe CVI cases.